| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 9MM | - |
| Operating Income | -42.1MM | +12% |
| Operating Expenses | 51.1MM | +25% |
| Net Income | -42.2MM | +13% |
| R&D | - | - |
| G&A | 10.3MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ:SMCI) leading the way with a 216% gain so far. However, analysts at the wealth management arm of Goldman Sachs think the tech sector may have run its course. They say it is time to start looking elsewhere. Investors would be better off taking the profits they’ve made in tech and de
A powerfully bullish new analyst take on the company helped it rally on the market.
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how ANI Pharmaceuticals (ANIP) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist, with top-line data anticipated by mid 2025 and H1 2026, respectivelyIND filings for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 and H2 2